Therapeutic Advances in Neurological Disorders

期刊简介：Therapeutic Advances in Neurological Disorders delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of neurological conditions. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in neurology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.The editors welcome original research articles across all areas of neurology.The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. The trial registry name and URL, and registration number must be included at the end of the abstract.The journal adheres to a single-blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees.

【译文】神经疾病治疗进展期刊提供最高质量的同行评审原创研究文章、评论和学术评论，涉及神经疾病医疗领域的开创性努力和创新研究。该期刊具有强烈的临床和药理学重点，面向国际神经科医生和研究人员的读者群体，为该领域最新研究和观点的快速传播提供一个在线论坛。编辑们欢迎所有神经学领域的原创研究文章。该期刊致力于发表临床研究。我们不发表临床前研究，包括基础实验室研究和动物研究。评论文章包括专家意见/观点评论（包括单药和药物类别评论）、叙述性评论和治疗领域评论。系统评价、荟萃分析、上市后和健康经济学及药经济学评论也欢迎。应遵循适当的EQUATOR网络报告指南（例如，随机对照试验的CONSORT和系统评价/荟萃分析的PRISMA）。该期刊支持ICMJE的要求，即临床试验必须在患者首次入组之前或同时在世界卫生组织批准的公共临床试验注册处注册。摘要结尾必须包括试验注册处名称和网址以及注册号。该期刊遵循单盲审稿流程，除非审稿人要求透露其身份，否则审稿人的姓名通常会被作者隐瞒。稿件至少由两名审稿人审阅。